Cerus Corporation — Form 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction of blood components. Commercial products include platelet and plasma systems, INTERCEPT Fibrinogen Complex, disposable kits, illuminators, spare parts, and maintenance services. The red blood cell system remains in development. This filing covers the three and six months ended June 30, 2022, compared with the corresponding 2021 periods.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $47.6 million | $37.8 million | $90.7 million | $67.3 million |
| Product revenue | $41.0 million | $31.5 million | $78.4 million | $54.9 million |
| Government contract revenue | $6.6 million | $6.3 million | $12.2 million | $12.5 million |
| Gross profit on product revenue | $21.3 million | $16.2 million | $40.6 million | $28.4 million |
| Product gross margin | 52% | 51% | 52% | 52% |
| Loss from operations | $(6.8) million | $(14.4) million | $(16.7) million | $(30.8) million |
| Net loss attributable to Cerus | $(8.4) million | $(15.4) million | $(20.7) million | $(32.8) million |
| Net loss per share | $(0.05) | $(0.09) | $(0.12) | $(0.19) |
Product revenue increased 30% in Q2 and 43% year to date, primarily from higher U.S. disposable platelet kit volumes following the FDA platelet-safety guidance effective October 1, 2021. Product gross margin was approximately 52% in both year-to-date periods. Total revenue increased 26% in Q2 and 35% year to date. The six-month operating loss margin improved to approximately 18% from 46%, while the net loss margin improved to approximately 23% from 49%.
- Research and development expense declined 11% in both the quarter and year-to-date periods, to $15.2 million and $29.3 million, respectively.
- Six-month selling, general and administrative expense increased 3% to $40.3 million; Q2 expense was essentially flat at $19.5 million.
- Six-month net cash used in operating activities was $21.8 million, compared with $26.1 million in 2021.
- Cash, cash equivalents, short-term investments, and restricted cash totaled $109.1 million at June 30, 2022, down from $131.6 million at December 31, 2021.
- Total debt was $69.7 million, including $28.7 million classified as current. The term loan bears an effective interest rate of approximately 7.50% and begins scheduled principal amortization in 2023 unless restructured.
- Working capital was $85.4 million, down from $108.5 million at December 31, 2021.
Material changes versus the prior comparable period
- U.S. platelet kit sales drove the substantial increase in product revenue; North American product revenue was $25.6 million in Q2 and $47.8 million year to date, compared with $14.6 million and $24.3 million, respectively, in 2021.
- Operating and net losses narrowed materially because of higher product revenue and gross profit, lower R&D spending, and relatively stable selling and administrative costs.
- Non-operating expense increased to $3.8 million year to date from $1.8 million, reflecting higher interest expense, foreign-exchange losses, and lower gains or higher losses on investments.
- Cash resources declined by $22.6 million from year-end, primarily reflecting operating cash use and investment in inventory and commercialization activities.
- In May 2022, Cerus entered a second amended and restated supply and manufacturing agreement with Fresenius extending manufacturing arrangements through December 31, 2031, subject to specified termination and renewal provisions.
- In June 2022, BARDA committed an additional $23 million, increasing committed funding to up to $149.5 million. Potential additional option periods could raise the total opportunity to $246.5 million through December 31, 2025, but are discretionary and may require up to $10 million of Cerus co-investment.
- No shares were sold under the at-the-market equity facility during the six months ended June 30, 2022; approximately $96.8 million remained available under the facility at June 30.
Guidance, outlook, risks, and unusual items
Management expects continued growth in INTERCEPT disposable kit revenue from U.S. expansion, broader adoption, and increased IFC revenue. Management also expects continuing losses and states that available cash, investments, product receipts, and government-contract receipts are expected to meet capital requirements for at least the next 12 months. The filing does not provide a clear numerical revenue or profitability guidance range.
- Management expects inflation, transportation costs, foreign-exchange movements, interest-rate increases, and supply-chain constraints to pressure costs and margins.
- Cerus relies heavily on Fresenius and other third parties, including sole or limited qualified suppliers, for manufacturing and key components. Capacity expansion, component obsolescence, and qualification of new facilities or suppliers could affect product availability.
- The redesigned illuminator remains subject to development and regulatory approval; current illuminator inventory may constrain sales until the redesign is approved and available.
- The red blood cell system is not commercialized. Clinical studies have experienced COVID-19-related enrollment delays, and the timing of European certification under the Medical Device Regulation remains uncertain.
- BARDA funding is subject to milestones, appropriations, option exercises, audits, and termination-for-convenience rights. Delays or reductions could materially reduce revenue and cash flow and force the company to curtail development.
- COVID-19, labor shortages, customer implementation delays, blood-component shortages, reimbursement uncertainty, competition, regulatory changes, and concentrated customers remain significant risks.
- Inventory totaled $45.5 million, including $17.7 million classified as non-current; the company recorded $0.4 million for potentially obsolete, expiring, or unsalable inventory at June 30, 2022.
- The company had $19.0 million of short-term and $2.7 million of long-term purchase commitments not recorded on the balance sheet, in addition to operating lease liabilities with a present value of $18.2 million.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting. No legal proceedings were reported.
Important facts for investors to verify
- Whether U.S. platelet-kit volume growth and IFC commercialization persist and translate into sustained operating leverage.
- The timing and amount of future BARDA reimbursements, option exercises, required co-investment, and any milestone or audit issues.
- Whether cash generation improves before scheduled debt principal payments begin in 2023 and whether refinancing or additional equity financing is required.
- Progress toward regulatory approval of the redesigned illuminator and availability of sufficient current-model inventory.
- Progress, clinical enrollment, supplier resolution, and regulatory timing for the red blood cell system.
- Exposure to Fresenius and other critical suppliers, inventory write-down risk, freight and inflationary costs, and foreign-exchange effects.
- Customer concentration, particularly the American Red Cross and Établissement Français du Sang, which represented significant portions of product revenue and accounts receivable.